A Phase I clinical study to evaluate the safety of Octreolin – an oral therapy for acromegaly patients manufactured by Chiasma – found no serious adverse events among treated subjects.

Acromegaly is a hormonal disorder that results from an excess of growth hormone.

The trial, conducted on 12 healthy volunteers, also showed that Octreolin had a pharmacokinetics profile similar to that of subcutaneously injected octreotide acetate.

Primary objectives of the study were to evaluate the safety, tolerability and PK of the three oral doses of Octreolin in comparison with the subcutaneous injection of octreotide acetate.

Biopharma company Chiasma said it will begin another trial by the end of the year to test the clinical efficacy of Octreolin in acromegaly patients.

The company said it is also developing the drug as a chronic treatment for patients with portal hypertension inhibition to prevent bleeding events and lower mortality rates.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.